If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
The UK COVID vaccination programme has progressed at an astonishing rate since the first patients received their doses in December 2020. It is well known that other vaccines including influenza and human papilloma virus (HPV) can result in reactive lymphadenopathy in the axilla and/or neck. Patients are now presenting via the two week wait neck lump clinic with supraclavicular fossa and low neck lymphadenopathy related to COVID vaccination, and to similar one stop breast clinics with axillary lymph nodes. In an audit of 80 patients seen over a period of one month, we found COVID vaccine-related low neck lymphadenopathy in four cases (5%), with an additional rectal cancer patient thought to have metastatic disease who presented with a Virchow type node. COVID vaccine-related lymphadenopathy should be considered in the differential diagnosis of low-neck nodes if they occurred shortly after vaccination, but it is important to exclude sinister disease using ultrasound and other investigations as necessary.
More than 30 million adults in the UK have now had their first dose and close to three million have also received the second dose. The amazing partnership between the NHS and patients will ensure that the number of recipients will increase over the summer months.
Both patients had received the vaccination in the left upper arm and had subsequently developed supraclavicular fossa lymphadenopathy a few days later that persisted for a few weeks. Ultrasound examination confirming reactive lymph nodes.
Since our report was published, others have published similar findings.
we prospectively audited presentations to the two-week neck lump clinic over a five week period with verified radiology reports on the Trust patient investigation results server (Minestrone). Patients were asked about their neck lump presentation, if they had received a recent COVID-19 vaccination, and if so whether they had also noticed any axillary lymphadenopathy.
A total of 80 patients were seen (16 per week). Four further patients, all of whom had been given a first dose of the vaccine a few days before noticing supraclavicular fossa lymph nodes were identified (5% incidence in our audit). All four had reactive lymphadenopathy confirmed on ultrasound with colour flow Doppler to assess vascularity (Fig. 1). One additional patient who had an anterior resection in 2020 for rectal carcinoma presented to the colorectal MDT with left sided supraclavicular lymphadenopathy. He was investigated for a possible Virchow node and metastatic spread with PET-CT. This confirmed increased metabolic activity at a recent left deltoid COVID vaccination site as well as left supraclavicular fossa lymphadenopathy (Fig. 2).
We wanted to raise awareness for colleagues of this seemingly increasing presentation to the neck lump clinic and how it should be considered in the differential diagnosis of low-neck nodes. It is clearly important to exclude more sinister causes including metastatic carcinoma from either above or below the clavicle, or lymphoma. In some instances, image guided fine needle aspiration cytology (FNAC) or core biopsy might be appropriate, or an interval follow up ultrasound scan may be considered.
Conflict of interests
We have no conflicts of interest.
Ethics statement/confirmation of patients’ permission